Heterogeneous-belief based incentive schemes for crowd sensing in mobile social networks

Jiajun Sun,Huadong Ma

DOI: https://doi.org/10.1016/j.jnca.2014.03.004

IF: 7.574

2014-06-01

Journal of Network and Computer Applications

Abstract:

What problem does this paper attempt to address?

Comparison of the Safety and Efficacy of Interferon Alpha-2a and Cyclosporine-A When Combined With Glucocorticoid in the Treatment of Refractory Behçet’s Uveitis: A Randomized Controlled Prospective Study

Yujing Qian,Yi Qu,Fei Gao,Minghang Pei,Anyi Liang,Junyan Xiao,Chan Zhao,Meifen Zhang

DOI: https://doi.org/10.3389/fphar.2021.699903

IF: 5.6

2021-07-19

Frontiers in Pharmacology

Abstract:Purpose: To evaluate and compare the efficacy and safety of interferon alpha-2a (IFN-α2a) and cyclosporine-A (CsA) in patients with refractory Behçet’s uveitis (BU). Methods: In this 12-month randomized, controlled, prospective trial, 26 participants (44 eyes) completed the study. Patients were randomly allocated to the IFN-α2a or CsA groups. All patients in both groups received a standardized prednisone burst and tapering schedule as per protocol. The primary outcome measures were response rate, complete remission rate, and tolerance rate. The secondary outcome measures included time to achieve complete remission, the logarithm of the minimum angle of resolution (logMAR) of best-corrected visual acuity (BCVA), and Behçet’s disease ocular attack score 24 (BOS24). T-tests and non-parametric tests were used to compare quantitative variables, and chi-square tests were performed to compare qualitative variables. Results: The response and complete remission rates were 85.7% (12/14 patients) and 50.0% (7/14 patients) in the IFN-α2a group, compared with 66.7% (8/12 patients) and 25.0% (3/12 patients) in the CsA group, respectively ( p > 0.05). Complete remission was achieved at 3.3 and 7.0 months after initiation of IFN-α2a and CsA ( p = 0.023). LogMAR BCVA significantly improved 1 month after IFN-α2a initiation (23 eyes) ( p = 0.002), and this beneficial effect remained statistically significant during the entire follow-up period ( p < 0.05); however, this improvement was not observed in the CsA group (21 eyes). At the endpoint, LogMAR BCVA in the IFN-α2a group was significantly better (0.22 vs. 0.31, p = 0.031) with a higher improvement rate (60.9 vs. 47.6%, p > 0.05). Moreover, compared to the CsA group, more eyes in the IFN-α2a group had a lower BOS24 score (87.0 vs. 57.1%, p = 0.042). None of the patients had any side effects that influenced the medication adherence. Conclusion: Compared to CsA plus corticosteroid, IFN-α2a plus corticosteroid appears to induce a better treatment response, a significantly greater improvement in visual acuity, and more stable remission of intraocular inflammation in a 12-month study period.

pharmacology & pharmacy
Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

Wenyan Peng,Xiuying Jiang,Lei Zhu,Xiaofeng Li,Qizhi Zhou,Ying Jie,Zhipeng You,Miaoqin Wu,Xiuming Jin,Xiaoyi Li,Shiyou Zhou

DOI: https://doi.org/10.2147/dddt.s370559

IF: 4.3188

2022-01-01

Drug Design Development and Therapy

Abstract:Purpose:To confirm the efficacy and safety of a novel ophthalmic cyclosporine A gel (CyclAGel, 0.05% CsA) in treating patients with moderate-to-severe dry eye disease (DED).Patients and Methods:The COSMO trial was a randomized, multicenter, double-masked, vehicle-controlled, phase III trial. Patients with moderate-to-severe DED were enrolled in 37 hospitals in China between November 2020 and April 2021. Eligible patients were randomized 1:1 to receive CyclAGel 0.05% or vehicle eye drops once nightly (QD). The primary endpoint was the proportion of subjects with at least a 1-point improvement in ICSS at day 84. Treatment-emergent adverse events (TEAEs) were recorded.Results:The full analysis set (FAS) included 315 and 312 participants in the CyclAGel and vehicle groups, respectively. The primary efficacy endpoint was achieved. The proportion of subjects with at least a 1-point improvement in ICSS from baseline to day 84 was significantly higher in the CyclAGel group than in the vehicle group (73.7% [232/315] vs 53.2% [166/312], P<0.0001). Significant improvements relative to the vehicle were also observed in the ICSS and Oxford scale scoring of corneal and conjunctival fluorescein staining at day 14, 42, and 84. The Schirmer tear test results were significantly higher in the CyclAGel group than in the vehicle group on days 14 and 84 (all P<0.05). The CyclAGel 0.05% was well tolerated, and the TEAEs were mostly mild. The most frequent treatment-related TEAE was eye pain (6.9% vs 1.6% in the CyclAGel and vehicle groups, respectively). No serious treatment-related TEAEs were reported.Conclusion:Clinically and statistically significant improvements in ICSS, tear production, and symptoms were observed in participants administered CyclAGel 0.05% QD for moderate-to-severe DED. CyclAGel 0.05% QD is a new effective, safe, and well-tolerated therapeutic option that might bring additional benefits of convenience and compliance as a once-A-day treatment for DED.
Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

Xinxin Jiang,Wei Shen,Xiujun Xu,Xiaogang Shen,Yiwen Li,Qiang He

DOI: https://doi.org/10.1007/s10157-017-1484-8

IF: 2.6212

2017-01-01

Clinical and Experimental Nephrology

Abstract:Background The purpose of this study was to conduct a meta-analysis examining the efficacy of cyclophosphamide, cyclosporin, and tacrolimus in treating steroid resistant nephrotic syndrome. Methods Medline, Cochrane, EMBASE, and Google Scholar were searched until May 02, 2017 using the keywords: immunosuppressive therapy, steroid-resistant nephrotic syndrome, cyclophosphamide, cyclosporine A, and tacrolimus. Inclusion criteria were randomized controlled trials (RCTs) including patients with SRNS treated with an immunosuppressive therapy or placebo. Results Seven RCTs were included, and the number of patients ranged from 30 to 131. Conventional pair-wise meta-analysis indicated a higher odds of complete or partial remission with tacrolimus as compared to cyclophosphamide [odds ratio (OR) 4.908, 95% confidence interval (CI) 2.278–10.576, P < 0.001], and cyclophosphamide (OR 0.143, 95% CI 0.028–0.721, P = 0.019) and placebo (OR 0.043, 95% CI 0.012–0.157, P < 0.001) were associated with a lower likelihood of complete or partial remission than cyclosporine. Bayesian analysis indicated that tacrolimus and cyclosporine were the best and the second-best agents for inducing a complete or partial remission (rank probability = 0.53 for tacrolimus and 0.46 for cyclosporine). Conclusion As compared to cyclophosphamide and cyclosporin, tacrolimus is more effective at inducing remission in patients with SRNS.
A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease

Zhenyu Zhong,Lingyu Dai,Qiuying Wu,Yu Gao,Yanlin Pu,Guannan Su,Xiaorong Lu,Fuxiang Zhang,Chong Tang,Yao Wang,Chunjiang Zhou,Peizeng Yang

DOI: https://doi.org/10.1038/s41467-023-39483-5

IF: 16.6

2023-06-24

Nature Communications

Abstract:Biologics are increasingly used to treat Vogt-Koyanagi-Harada disease, but head-to-head comparisons with conventional immunosuppressants are lacking. Here in this randomized trial (Chinese Clinical Trial Registry, ChiCTR2100043061), we assigned 110 patients (27 early-phase and 83 late-phase) to cyclosporine-based immunosuppressant strategy ( N = 56) or adalimumab-based biologic strategy ( N = 54), each combined with a modified corticosteroid regimen. The primary outcome is change from baseline in best-corrected visual acuity at week 26. The margin of non-inferiority for cyclosporine is −7 letters. The primary outcome is 11.2 letters (95% CI, 7.5 to 14.9) in the cyclosporine group and 6.3 letters (95% CI, 3.1 to 9.6) in the adalimumab group (difference, 4.9; 95% CI, 0.2 to 9.5; P < 0.001 for non-inferiority). The between-group difference is −0.8 letters (95% CI, −6.1 to 4.5) in early-phase disease and 5.7 letters (95% CI, 0.2 to 11.2) in late-phase. Serious adverse events are reported less frequently in the cyclosporine group than in the adalimumab group (0.70 vs. 1.21 events per patient-year). Here, we report that combined with a non-standard corticosteroid regimen, cyclosporine-based immunosuppressant strategy is non-inferior to adalimumab-based biologic strategy by 26 weeks for visual improvement in a cohort of patients with Vogt-Koyanagi-Harada disease, 75% of whom have a late-phase disease.

multidisciplinary sciences
A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.

Minjie Chen,Lan Gong,Xinghuai Sun,Yangshun Gu,Xiangge He,Jia Qu,Lili Wang,Mingzhi Zhang,Xingwu Zhong

DOI: https://doi.org/10.1185/03007995.2012.659723

2012-01-01

Current Medical Research and Opinion

Abstract:Objective: To compare the efficacy and safety of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in a Chinese population with ocular inflammation associated with blepharokeratoconjunctivitis (BKC). Research design and methods: This study was a multicenter, randomized, investigator-masked, parallel-group clinical trial. Patients aged >= 18 years with a clinical diagnosis of BKC in at least one eye received LE/T or DM/T administered 4 times daily for 2 weeks. At baseline and on days 3, 8, and 15 (visits 2, 3, and 4), clinical assessments of ocular signs and symptoms, visual acuity (VA), biomicroscopy, and intraocular pressure (IOP) were performed in both eyes. Main outcome measures: The primary efficacy endpoint was the change from baseline (CFB) to visit 4 in the signs and symptoms composite score in designated study eyes using a non-inferiority metric to compare LE/T to DM/T. Safety evaluation included adverse events, biomicroscopy findings, and changes in VA and IOP. Clinical trial registration: NCT number, NCT01028027. Results: A total of 308 patients were included in the per protocol population (n = 156 LE/T, n = 152 DM/T). A significant CFB in composite signs and symptoms was seen with both treatments at each follow-up visit (p<0.0001). The mean (SD) CFB at visit 4 was -11.63 (4.56) and -12.41 (4.71) in the LE/T and DM/T groups, respectively, and the upper bound of the 90% confidence interval for the difference was less than the prespecified non-inferiority margin. Comparable results were found for secondary efficacy outcomes. Patients treated with DM/T experienced a significantly greater increase in mean CFB in IOP compared to those treated with LE/T at all follow-up visits (p <= 0.0186) and nearly twice as many IOP elevations >= 5 mmHg (p = 0.0020). Conclusion: Treatment with LE/T was at least as effective as DM/T in Chinese patients with BKC and had a better safety profile with respect to change in IOP.
Efficacy and safety of adalimumab for inflammatory flare prevention in paediatric non-infectious anterior uveitis with peripheral retinal vascular leakage: a study protocol for a single-centre, randomised controlled trial

Hang Song,Chan Zhao,Yuelun Zhang,Donghui Li,Yujing Qian,Fei Gao,Junyan Xiao,Meifen Zhang

DOI: https://doi.org/10.1136/bmjopen-2022-062211

IF: 3.006

2022-12-08

BMJ Open

Abstract:Introduction Paediatric patients with chronic anterior uveitis are more prone to suffer from the chronic course of intraocular inflammation and adverse effects of long-term immunomodulatory therapy, either topical glucocorticosteroids or systemic immunomodulatory agents. The performance of adalimumab has been shown to be fairly favourable in treating refractory non-infectious uveitis, but the detailed indication is still under investigation. This study aims to assess the efficacy and safety of adalimumab for inflammatory flare prevention in non-infectious paediatric anterior uveitis with peripheral retinal vascular leakage, compared with methotrexate. Methods and analysis Children weighed ≥30 kg and aged between 4 and 16 years old with active non-infectious anterior uveitis with peripheral retinal vascular leakage on ultra-wildfield fluorescein fundus angiography will be included. They will be treated with a predesigned inflammatory control regimen to reach inflammatory quiescence in 1 month. After that they will be treated with either methotrexate 10 mg once a week or adalimumab once every 2 weeks and regularly followed up for 6 months. The primary endpoint is uveitis flare defined as defined as anterior chamber cell count grading increased from 0 to 1 within the observation period. Ethics and dissemination The study was approved by the Institutional Review Board of Peking Union Medical College Hospital, Beijing, China (Approved protocol V3, dated 27 July 2021. Approval number 25-ZS-3062) and has been registered on ClinicalTrials.gov. Written informed consent will be collected from every patient and their guardians prior to study participation. The results of this trial will be presented at local and international meetings and submitted to peer-reviewed journals for publication. Trial registration number NCT05015335.

medicine, general & internal
Comparative results of use and switching of anti-TNF-alpha agents in adult Behçet’s uveitis

Selma Mesen,Muhammet D Ozer,Muhammed Batur

DOI: https://doi.org/10.4103/ijo.ijo_2011_23

2024-02-05

Indian Journal of Ophthalmology

Abstract:Purpose: This study was planned to compare the clinical results and optical coherence tomography (OCT) data of patients who underwent adalimumab (ADA), infliximab (IFX) and switched protocols between these two methods in cases of Behçet’s associated uveitis (BAU). Methods: The patients with BAU who were treated with anti-TNF-α agents for at least one year were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA), the central macular thickness (CMT), and the subfoveal choroidal thickness (SFCT) of the patients at the last visit. Results: After a mean follow-up of 16.60 months, the rate of active inflammation decreased from 63.6% to 15.1%. Mean BCVA increased, mean CMT and mean SFCT decreased significantly at the last visit ( P < 0.001, P < 0.001, respectively). Conclusion: Anti-TNF-α treatment and switching protocols between these two agents effectively and safely control intraocular inflammation in BAU patients.

ophthalmology
Discussion on the Effect of Sympathectomy on Hypertensive Retinal Changes

G. Bourne,E. Tuckwell

DOI: https://doi.org/10.1177/003591574804101029

1948-10-01

Proceedings of the Royal Society of Medicine

Abstract:Renal functions: Blood urea 48 mg. 0%; urea concentration test-to 3-2%; urea clearance: 1st hour 131% of normal; 2nd hour 178% of normal. Urine: occasional hyaline and granular casts, otherwise normal. Bilateral two-stage transthoraco-lumbar sympathectomy on 13.5.47 and 3.6.47. Symptomatic improvement with freedom from headache. B.P. 185/140. August 2, 1947: B.P. 185/100. V.R. 6/6 pt. V.L. 6/5. Fundi: No haemorrhages or exudates or cedema. October 1947: B.P. 178/120; November and December: 180/120. January 180/125.
Clinical profile and management with immunosuppressants and biologics in Behcet's uveitis: A cohort of 25 patients from a tertiary eye care center in South India

Jeyasooriya Ramdoss,Prerana Singh,Arshee S Ahmed,Jyotirmay Biswas

DOI: https://doi.org/10.4103/ijo.IJO_1439_22

Abstract:Purpose: To report the clinical profile of Behcet's disease and its management with immunosuppressants and biologics in a cohort of 25 patients from a tertiary eye care center in South India. Methods: This was a retrospective, observational study. Records of 45 eyes of 25 patients between January 2016 and December 2021 were retrieved from the hospital database. Complete ophthalmic evaluation and systemic examination by the rheumatologist with appropriate investigations had been done. Results were analyzed using Statistical Package for the Social Sciences (SPSS) software. Results: Males (19, 76%) were found to be more affected than females (6, 24%). Mean age of presentation was 27.68 ± 11.08 years. Twenty patients had bilateral involvement (80%), and unilateral involvement was seen in five patients (20%). Seven eyes of four patients (16%) had isolated anterior uveitis, out of which one patient had unilateral and three patients had bilateral involvement. Twenty-six eyes of 16 patients (64%) had posterior uveitis, out of which six patients had unilateral and 10 had bilateral involvement. Twelve eyes of seven patients (28%) had panuveitis, out of which two patients had unilateral and five had bilateral involvement. Hypopyon was seen in five eyes (11.1%) and posterior synechiae in seven eyes (15.55%). Posterior segment findings included vitritis (24.44%), vasculitis (17.78%), retinitis (17.78%), disc hyperemia (11.11%), and disc pallor (8.89%). Steroids alone were given in five patients (20%) and intravenous methylprednisolone (IVMP) was given in four patients (16%). Immunosuppressive agents along with steroids were given in 20 patients (80%), of which azathioprine alone was given in seven patients (28%), cyclosporin alone was given in two patients (8%), mycophenolate mofetil alone was given in three patients (12%), combination of azathioprine and cyclosporin was given in six patients (24%), and combination of methotrexate and mycophenolate mofetil was given in one patient (4%). Biologics were given in 10 patients (40%) - adalimumab in seven patients (28%) and infliximab in three patients (12%). Conclusion: Behcet's disease is an uncommon uveitis in India. Addition of immunosuppressants and biologics to conventional steroid therapy gives better visual outcomes.
Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches

Biao Li,Haoran Li,Qun Huang,Yanlin Zheng

DOI: https://doi.org/10.1007/s10792-023-02808-w

IF: 2.029

2023-07-09

International Ophthalmology

Abstract:Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU.

ophthalmology
Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

Xin Guan,Zerui Zhao,Miaomiao Xin,Guangtao Xia,Qingrui Yang,Min Fu

DOI: https://doi.org/10.1111/1756-185x.15096

2024-02-01

International Journal of Rheumatic Diseases

Abstract:Abstract Aim This study aims to evaluate the long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha (anti‐TNF‐α) therapy for patients with Behcet's uveitis (BU) using meta‐analysis. Methods We searched the Web of Science and PubMed databases for eligible studies up to December 1, 2022. The quality of each identified study was assessed using the Joanna Briggs Institute's case series literature quality assessment tool. Statistical analysis was conducted using Stata 16.0 software with a random‐effects model. Results Twelve studies comprising 1156 patients with BU were included in our analysis. We found that 85.0% of patients achieved ocular inflammation remission after receiving anti‐TNF‐α treatment, with a 95% confidence interval (CI) ranging from 78.7% to 90.5%. Additionally, 77.4% (95% CI: 57.5%–92.5%) experienced an improvement in visual acuity (VA). Moreover, the pooled dose reduction of glucocorticoids (GCs) was 11.08 mg (95% CI: −13.34 mg to −8.83 mg). Throughout the follow‐up period, the cumulative retention rate of the medication was 67.3% (95% CI: 53.7%–79.6%). Serious adverse events occurred in 5.8% (95% CI: 3.1%–8.9%) of cases, with the three most common types being severe infusion or injection reactions (2.7%; 95% CI: 0.8%–5.4%), tuberculosis (1.3%; 95% CI: 0.0%–3.9%), and bacterial pneumonia (1.3%; 95% CI: 0.1%–3.4%). Subgroup analysis revealed that ocular inflammation remission rates were 89.3% (95% CI: 81.2%–95.5%) for adalimumab treatment and 83.7% (95% CI: 75.3%–90.8%) for infliximab treatment. The drug retention rate after adalimumab therapy was 70.3% (95% CI: 62.0%–78.0%) compared to 66.4% (95% CI: 48.6%–82.2%) for infliximab treatment. Furthermore, the incidence of severe infusion or injection reactions was 2.2% (95% CI: 0.1%–5.8%) following adalimumab treatment and 3.5% (95% CI: 0.7%–7.7%) following infliximab treatment. Conclusions Anti‐TNF‐α therapy represents an effective treatment for BU patients with favorable safety profile and high drug retention rate and a potential advantage of adalimumab over infliximab in terms of ocular inflammation remission, drug retention, and the incidence of severe infusion or injection reactions.

rheumatology
The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study

Hang Song,Chan Zhao,Junyan Xiao,Fei Gao,Donghui Li,Meifen Zhang

DOI: https://doi.org/10.3389/fmed.2022.813696

IF: 3.9

2022-03-29

Frontiers in Medicine

Abstract:Purpose This study is aimed to assess the efficacy of adalimumab in alleviating peripheral vascular leakage in pediatric chronic anterior uveitis patients, along with its ability to improve best-corrected visual acuity (BCVA) and inflammation parameters, its efficacy in reducing topical glucocorticosteroids (GCs) and systemic immunomodulatory therapy (IMT), and its safety profile. Methods A self-controlled study of pediatric chronic anterior uveitis patients who presented with peripheral retinal vascular leakage on ultra-widefield fluorescein fundus angiography and underwent adalimumab treatment was conducted. The primary outcome was the extent of retinal vascular leakage at the 3- and 6-month follow-up visits. Secondary outcomes included BCVA, inflammation parameters (fresh keratic precipitates, anterior chamber cell, and vitreous cell grades), frequency of topical glucocorticosteroid eye drops, IMT load, and adverse effects at the 3- and 6-month follow-up visits. Results Twenty patients with a mean age of 9.30 ± 3.26 years old were included. The mean follow-up period was 9.0 ± 3.0 months, with all patients followed up for at least 6 months. At the 3- and 6-month follow-ups, the peripheral vascular leakage score decreased significantly (2.87, 95% CI (2.14, 3.60) , p < 0.001 for 3 months, 2.75, 95% CI (1.76, 3.73) , p < 0.001 for 6 months). Alongside BCVA ( p = 0.013 for 3 months, p = 0.005 for 6 months) was improved significantly, inflammatory parameters represented by fresh keratic precipitates, anterior chamber cell, and vitreous cell grades were improved significantly ( p < 0.001, p < 0.001, for all parameters) and topical GC usage was significantly reduced ( p < 0.001, p < 0.001) at 3 and 6 months. There was also a statistically significant reduction in systemic IMT load at 6 months ( p < 0.001). Adverse events in the observation period included local redness around the injection site and mild upper respiratory symptoms. Conclusion Adalimumab could effectively alleviate peripheral vascular leakage in pediatric patients with chronic anterior uveitis. It could also be helpful in improving BCVA and inflammation parameters and decreasing topical glucocorticosteroid eye drops and systemic IMT. Adalimumab is generally safe for pediatric uveitis.

medicine, general & internal
[Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease]

S W Liu,Y H Zhao,J Ma,Z Shen,B H Hu,R M Peng,J Hong

DOI: https://doi.org/10.3760/cma.j.cn112142-20221112-00585

2023-10-11

Abstract:Objective: To evaluate the effectiveness and safety of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in treating severe dry eye associated with chronic graft-versus-host disease (cGVHD). Methods: This non-randomized concurrent control trial enrolled 83 eyes from 83 patients with cGVHD-associated severe dry eye. The treatment had two phases. During the initial shock treatment period (0-3 months), 44 patients received 0.05% cyclosporine A eye drops (4 times/day; group A) and 39 patients received 0.1% tacrolimus eye drops (twice/day; group B) alongside basic treatment. In the maintenance treatment period (3-6 months), both groups used 0.05% cyclosporine A eye drops (twice/day) and sodium hyaluronate. Examinations were conducted at 1, 3, and 6 months after treatment initiation, assessing the Ocular Surface Disease Index (OSDI), corneal fluorescein staining (CFS) score, and fluorescein tear break-up time (BUT) for efficacy. visual acuity and intraocular pressure (IOP) were evaluated for safety, and patients' post-medication irritation symptoms were recorded. Results: The study included 52 males and 31 females, aged (28.57±15.67) years. After 1 month of treatment, the CFS score in group A significantly decreased from 10.0 (6.0, 14.0) to 5.0 (3.0, 8.5) (P<0.001). in group B, the CFS score also significantly decreased from 10.0 (6.0, 15.0) to 6.0 (2.0, 10.0), and the BUT increased from 2.0 (1.0, 2.0) s to 2.0 (1.8, 3.3) s (P<0.001). No significant OSDI decrease was observed in either group. No significant differences were found in OSDI, CFS score, and BUT between the two groups. After 3 months, group A showed significant improvement in OSDI, CFS score, and BUT (P<0.05), while group B only demonstrated significant CFS score decrease (P<0.05). OSDI was significantly lower in group A than group B (P<0.05). No significant differences were noted in CFS score and BUT between groups. After 6 months, OSDI, CFS score, and BUT were 18.9 (9.3, 34.2), 7.0 (3.0, 8.5), and 2.0 (1.0, 3.0) s in group A, and 10.9 (3.6, 35.4), 5.5 (2.8, 10.0), and 2.0 (1.0, 10.0) s in group B. In both groups, CFS scores significantly decreased and BUT increased (P<0.05). Visual acuity improved significantly in group A at 1, 3, and 6 months (P<0.05), while no significant changes were seen in group B. Irritation symptoms were transient and self-resolving in both groups. Conclusions: Both 0.05% cyclosporine A and 0.1% tacrolimus eye drops, when combined with local glucocorticoids, exhibited significant anti-inflammatory effects, effectively and safely treating severe dry eye in cGVHD patients. Although the onset of 0.05% cyclosporine A was slower than 0.1% tacrolimus, it offered more stable long-term effects and better symptom improvement.
Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome

David Saadoun,Georgina Maalouf,Matheus Vieira,Salim Trad,Estibaliz Lazaro,Karim Sacre,Aurelie Plessier,Thomas Sené,Isabelle Koné-Paut,Nicolas Noel,Arsène Mekinian,Marc Lambert,Emmanuel Ribeiro,Tristan Mirault,Nicolas Mele,Azeddine Dellal,Olivier Fain,Isabelle Melki,Laurent Chiche,Julien Gaudric,Alban Redheuil,Elisabeth Maillart,Amine Ghembaza,Anne-Claire Desbois,Adrien Mirouse,Fanny Domont,Gaëlle Leroux,Yasmina Ferfar,Aude Rigolet,Jean-François Viallard,Mathieu Vautier,Matthieu Resche-Rigon,Patrice Cacoub

DOI: https://doi.org/10.1056/EVIDoa2300354

Abstract:Background: Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's syndrome is not known. Methods: In this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria for Behçet's syndrome who had major vascular or central nervous system involvement to receive either intravenous infliximab (5 mg/kg at weeks 0, 2, 6, 12, and 18) or cyclophosphamide (0.7 g/m2 intravenously at weeks 0, 4, 8, 12, 16, and 20, with a maximal dose of 1.2 g/infusion). All patients received the same glucocorticoid regimen. The primary outcome was complete response (clinical, biological, and radiological remission with a daily prednisone dose ≤0.1 mg/kg) at week 22. Results: Between May 2018 and April 2021, 52 patients with severe Behçet's syndrome (n=37 [71%] with vascular Behçet's syndrome and n=15 [29%] with neuro-Behçet's syndrome) were randomly assigned to receive either infliximab or cyclophosphamide. Complete response was achieved by 22 out of 27 (81%) and 14 out of 25 (56%) patients in the infliximab and cyclophosphamide treatment groups, respectively (estimated difference, 29.8 percentage points; 95% credible interval, 6.6 to 51.7). The posterior probability that at least 70% of treated individuals achieved complete response by week 22 was 97.4% for infliximab and 6.0% for cyclophosphamide. Overall, adverse events were recorded in 8 out of 27 (29.6%) patients receiving infliximab and 16 out of 25 (64%) patients receiving cyclophosphamide (estimated difference, -32.3 percentage points; 95% credible interval, -55.2 to -6.6). Serious adverse events were reported in 15% and 12% of patients receiving infliximab and cyclophosphamide, respectively. Conclusions: Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded by the French Ministry of Health.).
Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways

Megan M. Weivoda,M. Ruan,Christine M. Hachfeld,Larry Pederson,A. Howe,R. Davey,J. Zajac,Yasuhiro Kobayashi,B. Williams,J. Westendorf,S. Khosla,M. Oursler

DOI: https://doi.org/10.1002/jbmr.2599

IF: 6.39

2016-01-01

Journal of Bone and Mineral Research

Abstract:Although there has been extensive characterization of the Wnt signaling pathway in the osteoblast lineage, the effects of Wnt proteins on the osteoclast lineage are less well studied. We found that osteoclast lineage cells express canonical Wnt receptors. Wnt3a reduced osteoclast formation when applied to early bone‐marrow macrophage (BMM) osteoclast differentiation cultures, whereas late addition did not suppress osteoclast formation. Early Wnt3a treatment inactivated the crucial transcription factor NFATc1 in osteoclast progenitors. Wnt3a led to the accumulation of nuclear β‐catenin, confirming activation of canonical Wnt signaling. Reducing low‐density lipoprotein receptor‐related proteins (Lrp) 5 and Lrp6 protein expression prevented Wnt3a‐induced inactivation of NFATc1; however, deletion of β‐catenin did not block Wnt3a inactivation of NFATc1, suggesting that this effect was mediated by a noncanonical pathway. Wnt3a rapidly activated the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and pharmacological stimulation of cAMP/PKA signaling suppressed osteoclast differentiation; Wnt3a‐induced NFATc1 phosphorylation was blocked by inhibiting interactions between PKA and A‐kinase anchoring proteins (AKAPs). These data indicate that Wnt3a directly suppresses osteoclast differentiation through both canonical (β‐catenin) and noncanonical (cAMP/PKA) pathways in osteoclast precursors. In vivo reduction of Lrp5 and Lrp6 expressions in the early osteoclast lineage via Rank promoter Cre recombination reduced trabecular bone mass, whereas disruption of Lrp5/6 expression in late osteoclast precursors via cathepsin K (Ctsk) promoter Cre recombination did not alter the skeletal phenotype. Surprisingly, reduction of Lrp5/6 in the early osteoclast lineage decreased osteoclast numbers, as well as osteoblast numbers. Published studies have previously noted that β‐catenin signaling is required for osteoclast progenitor proliferation. Our in vivo data suggest that Rank promoter Cre‐mediated deletion of Lrp5/6 may similarly impair osteoclast progenitor proliferation. © 2015 American Society for Bone and Mineral Research.
Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

Ana Belen Rivas,Amanda Lopez-Picado,Valentina Calamia,Ester Carreño,Lidia Cocho,Miguel Cordero-Coma,Alex Fonollosa,Felix M Francisco Hernandez,Angel Garcia-Aparicio,Javier Garcia-Gonzalez,Jose Juan Mondejar,Leticia Lojo-Oliveira,Llucí Martínez-Costa,Santiago Munoz,Diana Peiteado,Jose Antonio Pinto,Beatriz Rodriguez-Lozano,Esperanza Pato,David Diaz-Valle,Elena Molina,Luis Alberto Tebar,Luis Rodriguez-Rodriguez,Mara Albert Fort,Mayte Ariño Gutierrez,Pedro Arriola Villalobos,Joseba Artaraz Beobide,Antonio Atanes Sandoval,Jose Manuel Sanchez,Francisco Blázquez,Pablo Borges Deniz,Lara Borrego Sanz,Gabriela Bustamante Sanchez-Arnedo,Bruno Casco Silva,Ricardo Cuiña Sardiña,Almudena De Pablo Cabrera,Maria Del Mar Esteban Ortega,Patricia Fernandez Puente,Dalifer Dayanira Nuñez,Javier Garcia Bella,Sara Garcia Carazo,Luis Garcia Onrubia,Jose Maria Morales,Jose Antonio Fernandez,Vanesa Hernandez Hernandez,Inés Hernanz Rodriguez,Jose Maria Cantalapiedra,Ventura Hidalgo Barrero,Maria De Jovani Casano,Maria Isabel Rodriguez,Sara López Sierra,Virginia Lozano Lopez,Alfredo Madrid Garcia,Rosalia Mendez Fernandez,Pilar Nozal Aranda,Eugenio Perez Blazquez,Chamaida Plasencia Rodriguez,Sheila Recuero Diaz,Ignacio Robles Barrena,Esther Rodriguez Almaraz,Fayna Maria Gonzalez,Guadalupe Rodriguez Martinez,Fredeswinda Isabel Bueno,Ioana Ruiz Arruza,Beatriz Sanchez Marugan,Olga Sanchez Pernaute,Armelle Schlinker Giraud,Alvaro Seijas Lopez,Patricia Simon Alonso,Marta Tejera Santana,Elia Valls Pascual

DOI: https://doi.org/10.1136/bmjopen-2021-051378

IF: 3.006

2022-03-01

BMJ Open

Abstract:Introduction Non-infectious uveitis include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed in monotherapy or in combination. Several observational studies showed that the use of ISDs in combination could be more effective than and as safe as their use in monotherapy. However, a direct comparison between these two treatment strategies has not been carried out yet. Methods and analysis The Combination THerapy with mEthotrexate and adalImumAb for uveitis (CoTHEIA) study is a phase III, multicentre, prospective, randomised, single-blinded with masked outcome assessment, parallel three arms with 1:1:1 allocation, active-controlled, superiority study design, comparing the efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis. We aim to recruit 192 subjects. The duration of the treatment and follow-up will last up to 52 weeks, plus 70 days follow-up with no treatment. The complete and maintained resolution of the ocular inflammation will be assessed by masked evaluators (primary outcome). In addition to other secondary measurements of efficacy (quality of life, visual acuity and costs) and safety, we will identify subjects’ subgroups with different treatment responses by developing prediction models based on machine learning techniques using genetic and proteomic biomarkers. Ethics and dissemination The protocol, annexes and informed consent forms were approved by the Reference Clinical Research Ethic Committee at the Hospital Clínico San Carlos (Madrid, Spain) and the Spanish Agency for Medicines and Health Products. We will elaborate a dissemination plan including production of materials adapted to several formats to communicate the clinical trial progress and findings to a broad group of stakeholders. The promoter will be the only access to the participant-level data, although it can be shared within the legal situation. Trial registration number 2020-000130-18; NCT04798755 .

medicine, general & internal
Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet's Disease

Nuria Barroso-García,José Luis Martín-Varillas,Iván Ferraz-Amaro,Lara Sánchez-Bilbao,Adrián Martín-Gutiérrez,Alfredo Adán,Inés Hernanz-Rodríguez,Emma Beltrán-Catalán,Miguel Cordero-Coma,David Díaz-Valle,Marisa Hernández-Garfella,Lucía Martínez-Costa,Manuel Díaz-Llopis,José M. Herreras,Olga Maíz-Alonso,Ignacio Torre-Salaberri,Antonio Atanes-Sandoval,Santos Insúa,Raquel Almodóvar-González,Patricia Fanlo,Juan Ramón De Dios Aberasturi,Ángel García-Aparicio,Sergio Rodríguez-Montero,Vega Jovaní,Patricia Moya-Alvarado,Eva Peña Sainz-Pardo,Vanesa Calvo-Río,Rosalía Demetrio-Pablo,José Luis Hernández,Ricardo Blanco

DOI: https://doi.org/10.3390/jcm13237388

IF: 3.9

2024-12-05

Journal of Clinical Medicine

Abstract:Background: The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. Objectives: To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD. Methods: Multicenter study of BD-CME patients with no response to glucocorticoids (GCs) and at least one conventional immunosuppressive drug. At baseline, all patients presented CME, defined by OCT > 300 μ. The effectiveness of ADA, IFX and CZP was assessed over a 2-year period from baseline using the following ocular parameters: macular thickness (μm), visual acuity (BCVA), anterior chamber (AC) cells and vitritis. Mixed-effects regression models were applied. Results: a total of 50 patients (75 eyes) were studied (ADA = 25; IFX = 15 and CZP = 10). No significant differences in demographic parameters were found among the three groups. However, individuals in the CZP group had a significantly extended time from diagnosis to treatment onset (72 (36–120) months, p = 0.03) and had received a higher number of biological therapies (1.7 ± 1.1) compared to the ADA and IFX groups. Within the CZP group, ADA and IFX were previously administrated in seven patients. After 2 years of follow-up, a rapid and sustained reduction in macular thickness was noted in all three groups with no significant differences between them. Additionally, enhancements in BCVA, AC cells and vitritis were also observed. No serious adverse events were reported in the CZP group, although one isolated case of bacteremia was documented in the ADA group. ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX. Conclusions: ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX.

medicine, general & internal
Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies

Tomona Hiyama,Yosuke Harada,Yoshiaki Kiuchi

DOI: https://doi.org/10.1080/09273948.2020.1857791

2021-02-09

Ocular Immunology and Inflammation

Abstract:Objective: To assess the efficacy and safety of adalimumab treatment in patients with Non-infectious uveitis. Methods: This was a single-center retrospective chart review of patients with active Non-infectious uveitis who had received adalimumab in Japan. Outcome variables included change in systemic immunosuppressive treatment, intraocular inflammation, visual acuity, and relapse rate. Results: In total, 48 patients were included. After the initiation of adalimumab, more than 80% of the patients received systemic corticosteroid ≤5 mg from 3 months onwards. Intraocular inflammation, relapse rate, and visual acuity showed persistent improvement. Adalimumab and methotrexate combination therapy was required in 71.4% of the patients with Vogt–Koyanagi–Harada disease/sympathetic ophthalmia, whereas it was required in only 18.0% of the patients with Behçet's disease. There were no serious side effects that required discontinuation of adalimumab. Conclusion: Adalimumab is efficacious and safe for the treatment of patients with Non-infectious uveitis. Differences in the efficacy of adalimumab treatment may exist between patients with Vogt–Koyanagi–Harada disease/sympathetic ophthalmia and patients with Behçet's disease.

ophthalmology
A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.

Minjie Chen,Lan Gong,Xinghuai Sun,Hanping Xie,Yueqin Zhang,Liuhe Zou,Jia Qu,Yumin Li,Jia He

DOI: https://doi.org/10.1089/jop.2009.0145

2010-01-01

Journal of Ocular Pharmacology and Therapeutics

Abstract:Purpose: The goals of this study were to compare the efficacy and safety profile of topical cyclosporine 0.05% versus vehicle in Chinese patients with moderate to severe dry eye disease. Methods: In this multicenter, randomized, double-blind, vehicle-controlled, parallel-group study, 233 dry eye patients were allocated to receive either cyclosporine 0.05% or vehicle twice daily for 8 weeks. Primary outcome was the difference between groups, in total score of 4 symptoms and 4 signs change from baseline at weeks 2, 4, and 8. Changes in symptoms (ocular dryness, foreign body sensation, photophobia and burning) and signs (conjunctival hyperemia, Schirmer test, tear Break-up time (BUT), and corneal punctate fluorescein staining) at weeks 2, 4, and 8 as well as frequency of administration of concomitant artificial tears, were considered as secondary outcomes. The safety profile was evaluated by examining adverse events, changes in visual acuity, and ocular tolerance. Results: Greater improvements of the total score were seen in cyclosporine 0.05% group than in the vehicle group at all follow-up times (P<0.01). Improvements in ocular dryness at week 8 (P=0.040) and foreign body sensation during weeks 4 and 8 (P<0.020) were significantly greater with cyclosporine. In addition, compared with the vehicle, cyclosporine significantly improved 2 objective dry eye disease signs: corneal staining at weeks 4 (P=0.025) and 8 (P=0.050) and the Schirmer test at week 4 (P=0.035). However, no between-group difference approached statistical significance in photophobia, burning, BUT value, conjunctival hyperemia and frequency of administration of concomitant artificial tears at any follow-up times (P>0.05). The cumulative frequency of adverse events did not significantly differ between the groups (P=0.519), which were 11.21% and 8.55%, respectively. There were no patients who experienced reduced visual acuity. Conclusion: Cyclosporine 0.05% ophthalmic emulsion is an effective and safe treatment for Chinese patients with moderate to severe dry eye disease.
Combination therapy for Behçet uveitis

Holly Webster

DOI: https://doi.org/10.1038/s41584-024-01173-x

IF: 32.286

2024-10-05

Nature Reviews Rheumatology

Abstract:A study has compared the safety and efficacy of three different immunomodulatory drugs combined with glucocorticoids for the treatment of Behçet uveitis.

rheumatology

Heterogeneous-belief based incentive schemes for crowd sensing in mobile social networks

Comparison of the Safety and Efficacy of Interferon Alpha-2a and Cyclosporine-A When Combined With Glucocorticoid in the Treatment of Refractory Behçet’s Uveitis: A Randomized Controlled Prospective Study

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease

A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.

Efficacy and safety of adalimumab for inflammatory flare prevention in paediatric non-infectious anterior uveitis with peripheral retinal vascular leakage: a study protocol for a single-centre, randomised controlled trial

Comparative results of use and switching of anti-TNF-alpha agents in adult Behçet’s uveitis

Discussion on the Effect of Sympathectomy on Hypertensive Retinal Changes

Clinical profile and management with immunosuppressants and biologics in Behcet's uveitis: A cohort of 25 patients from a tertiary eye care center in South India

Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches

Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study

[Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease]

Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome

Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways

Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet's Disease

Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies

A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.

Combination therapy for Behçet uveitis